Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib

NCT01523340 is registered in ClinicalTrials.gov with Chonnam National University Hospital as lead sponsor.

NCT NCT01523340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01523340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib
Lead sponsor
Chonnam National University Hospital
Phase
Observational
Overall status
Completed
Start date
September 30, 2011
Completion date
November 30, 2017
Enrollment
196 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic, non-small cell lung cancer recurrent